Innovent Biologics
(OTC) IVBXF
Innovent Biologics Financials at a Glance
Market Cap
$17.75B
Revenue (TTM)
$18.88B
Net Income (TTM)
$149.07M
EPS (TTM)
$0.09
P/E Ratio
107.35
Dividend
$0.00
Beta (Volatility)
0.03 (Low)
Dividend
$0.00
Beta (Volatility)
0.03 (Low)
Price
$10.23
Volume
1,000
Open
$10.23
Price
$10.23
Volume
1,000
Open
$10.23
Previous Close
$10.23
Daily Range
$10.23 - $10.23
52-Week Range
$5.00 - $15.12
Dividend
$0.00
Beta (Volatility)
0.03 (Low)
Price
$10.23
Volume
1,000
Open
$10.23
Previous Close
$10.23
Daily Range
$10.23 - $10.23
52-Week Range
$5.00 - $15.12
IVBXF News
IVBXF: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Innovent Biologics
Industry
Biotechnology
Sector
Health CareEmployees
5,659
CEO
De Chao Yu, PhD
Website
www.innoventbio.comHeadquarters
Suzhou, 215123, CN
IVBXF Financials
Key Financial Metrics (TTM)
Gross Margin
76%
Operating Margin
6%
Net Income Margin
10%
Return on Equity
8%
Return on Capital
4%
Return on Assets
5%
Earnings Yield
0.93%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$17.75B
Shares Outstanding
1.74B
Volume
1.00K
Short Interest
0.00%
Avg. Volume
7.39K
Financials (TTM)
Gross Profit
$7.91B
Operating Income
$755.87M
EBITDA
$480.28M
Operating Cash Flow
$1.29B
Capital Expenditure
$1.71B
Free Cash Flow
$418.39M
Cash & ST Invst.
$7.88B
Total Debt
$2.83B
Innovent Biologics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$5.95B
+120.4%
Gross Profit
$4.60B
+139.6%
Gross Margin
77.26%
N/A
Market Cap
$17.75B
N/A
Market Cap/Employee
$3.14M
N/A
Employees
5,659
N/A
Net Income
$834.32M
+699.6%
EBITDA
$1.03B
+288.4%
Quarterly Fundamentals
Net Cash
$6.16B
+46.7%
Accounts Receivable
$1.72B
+10.5%
Inventory
$1.13B
-13.2%
Long Term Debt
$2.26B
-23.9%
Short Term Debt
$1.11B
+133.6%
Return on Assets
4.80%
N/A
Return on Invested Capital
3.91%
N/A
Free Cash Flow
$211.19M
+117.3%
Operating Cash Flow
$313.76M
+150.4%